Search

Displaying results 1951 - 1960 of 8196 in total
  1. Drug

    Lonoctocog alfa

    go.drugbank.com/drugs/DB13998
    ApprovedInvestigational

  2. Drug

    Deleobuvir

    go.drugbank.com/drugs/DB14850
    Investigational

    Deleobuvir is under investigation in clinical trial NCT01983566 (Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

  3. Drug

    Corticorelin ovine triflutate

    go.drugbank.com/drugs/DB09067
    Approved

    However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome. … If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease.

  4. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    As an inhalant, it also has psychoactive effect which has led to illegal drug use. … Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning.

  5. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).

  7. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  8. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  9. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment fo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.